<DOC>
	<DOCNO>NCT01324739</DOCNO>
	<brief_summary>Rationale : B type natriuretic peptide ( BNP ) hormone release cardiomyocytes response myocyte stretch serf reliable biomarker diagnosis cardiac dysfunction heart failure . Recent observation speak distinct connection chronic heart failure diabetes mellitus . Objective : The study set investigate role BNP parameter glucose metabolism placebo control cross-over study healthy volunteer . Methods Results : Ten participant ( 25±1 year ; BMI 23±1 kg/m2 ; fast glucose 83±2 mg/dL ) receive either placebo 3 pmol/kg/min BNP 32 intravenously 4h . One hour begin BNP/placebo infusion , 3h intravenous glucose tolerance test ( 0.33 g/kg glucose + 0.03 U/kg insulin 20 min ) perform plasma glucose , insulin C peptide frequently measure . BNP increase initial glucose distribution volume ( 13±1 % BW vs. 11±1 , P &lt; 0.002 ) , lead overall reduction glucose concentration ( P &lt; 0.001 ) especially initial 20 min test ( P=0.001 ) , accompany reduction initial C peptide level ( 4.3±0.4 ng/mL vs. 4.9±0.3 , P=0.015 ) . BNP impact beta cell function , insulin clearance insulin sensitivity . Discussion : Intravenous administration BNP increase glucose initial distribution volume lower plasma glucose concentration glucose load without affect beta cell function insulin sensitivity speak concept BNP diabetogenic , improve metabolic status patient heart failure . This open new question regard BNP induce difference glucose availability signal several organs/tissues .</brief_summary>
	<brief_title>B-type Natriuretic Peptide Glucose Metabolism</brief_title>
	<detailed_description>In one recent study investigate insulin sensitivity ( OGIS index ) insulin secretion ( beta cell function insulinogenic index , IGI ) patient heart insufficiency frequently sample oral glucose tolerance test ( 21 ) . Insulin sensitivity impair CHF compare control ( OGIS : 354±14 ml/min/m2 vs. 450±20 ; p &lt; 0.003 ) . Also beta cell function reduce ( IGI : 100±14 vs. 150±45 pmolINS/pmolGLUC ) . Interestingly significant inverse correlation exist BNP IGI ( r=0.41 , p &lt; 0.05 ) ( 21 ) . The relationship BNP glucose metabolism partially investigate . Plasma BNP rise response hyperglycemia , influence hyperinsulinemia ( 22 , 23 ) . On side , physiological role BNP beta cell function insulin sensitivity investigate date . As BNP level rise degree heart insufficiency insulin resistance correlate degree cardiomyopathy , hypothesize BNP influence glucose metabolism healthy men . One gold standard investigation beta cell function peripheral insulin sensitivity insulin-modified frequently sample intravenous glucose tolerance test ( FSIGT ) . The FSIGT consist give intravenously glucose bolus time point 0 follow intravenous administration insulin time point 20 minute ( 18,19 , 20 ) . The determination glucose , insulin C-peptide frequent interval till time point 180 minute allow calculation acute insulin response , glucose effectiveness , insulin clearance insulin sensitivity minimal model analysis ( 13 ) The intravenous administration 3 pmol/kg/min BNP achieve plateau increase BNP plasma concentration 60 minute . In previous publication , infusion administer 4 hour , achieve steady state plasma BNP time point 60 minute 240 minute ( 17 ) . Using already establish protocol , aim maintain constantly high plasma BNP level throughout three hour FSIGT . The combination BNP ( 17 ) FSIGT ( 13 ) protocol interventional study adequate mean investigate impact BNP glucose metabolism healthy subject . The present study aim investigate effect intravenous infusion BNP-32 ( American Peptide , Calif. , US ) beta cell function insulin sensitivity FSIGT healthy volunteer . -65 , -60 , -30 , 0 , 3 , 4 , 5 , 6 , 8 , 10 , 14 , 19 , 22 , 27 , 30 , 35 , 40 , 50 , 60 , 70 , 90 , 100 , 120 , 140 , 150 180 min measurement glucose , insulin C-peptide ( 8 ml per time point : time point -30 , 0 , 3 , 4 , 5 , 6 , 8 , 10 , 14 , 19 , 22 , 27 , 30 , 35 , 40 , 50 , 70 , 100 , 140 180 min ) , measurement BNP NT-proBNP ( 4 ml per time point : time point -65 , -60 , -30 , 0 , 30 , 60 , 90 , 120 , 150 180 min ) measurement plasma sodium , potassium creatinine ( 8 ml per time point : time point -60 , 60 180 minute ) . Primary outcome parameter area curve insulin ( AUCinsulin ) time point -30 180 min . Secondary outcome parameter AUCglucose AUCc-peptide time point -30 180 min , BNP- NT-proBNP level time point -65 180 , plasma sodium , potassium creatinine time point -60 180 . On study day volunteer come study room around 07:45 a.m. overnight fasting . After weigh , remain bed throughout study , except stand pas urine . Two vein flow needle ( Venflon , Helsingborg , Sweden ) insert antecubital vein right leave arm administration infusion blood sample respectively . The subject rest approximately 15 minute obtain baseline blood sample ( time point - 65 minute ) . 3.0 pmol/kg/min human BNP-32 ( American Peptide , Calif. , US ) solve Haemaccel ( 10 mL/h ) , placebo ( Haemaccel , 10 mL/h , alone ) continuously administer 4 hour , time point -60 180 minute , use syringe pump ( Treonic , Vickers Medical , Basingstoke , United Kingdom ) . A washout period least 2 week administration BNP placebo two different study day . This protocol use study Lainchbury et al . ( 17 ) . 330 mg/kg body weight glucose administer bolus 30 second time point 0-0.5 minute . 0.03 IU/kg rapidly act insulin ( Actrapid , Novo-Nordisk , Denmark ) infuse intravenously 5 minute start time point 20 . Blood sample collect time point : -65 , -60 , -30 , 0 , 3 , 4 , 5 , 6 , 8 , 10 , 14 , 19 , 22 , 27 , 30 , 35 , 40 , 50 , 60 , 70 , 90 , 100 , 120 , 140 , 150 180 min measurement glucose , insulin C-peptide ( 8 ml per time point : time point -30 , 0 , 3 , 4 , 5 , 6 , 8 , 10 , 14 , 19 , 22 , 27 , 30 , 35 , 40 , 50 , 70 , 100 , 140 180 min ) , measurement BNP NT-proBNP ( 4 ml per time point : time point -65 , -60 , -30 , 0 , 30 , 60 , 90 , 120 , 150 180 min ) measurement plasma sodium , potassium creatinine ( 8 ml per time point : time point -60 , 60 180 minute ) . A final safety blood sample collect time point 270 min plasma sodium , potassium , creatinine BNP , NT-proBNP , sodium , potassium , creatinine , GPT , gamma-GT , total bilirubin ensure ( NT-pro ) BNP level return baseline parameter within normal range . Total volume blood withdrawal 230 ml . When void , subject ask collect urine excrete study period ( -65 till 180 minute ) . measurement sodium , potassium creatinine excretion . Heart rate blood pressure continuously monitor whole study . If systolic blood pressure low 85 mmHg heart rate le 50 beat per minute BNP infusion stop . Data analysis estimate insulin sensitivity , ß-cell secretion , insulin clearance , insulin hepatic extraction insulin appearance rate do minimal model computer analysis frequently sample intravenous glucose tolerance test</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>write informed consent disease history BNP level within normal range Normal renal function ( serum creatinine 1.3 mg/dL and/or creatinin clearance great 80ml/min ) Normal ECG systolic blood pressure &lt; 90 mmHg subject medication abnormal glucose metabolism history anaphylaxis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>